• Rigel Pharmaceuticals (RIGL) shares soared today after the company announced positive data on its second mid-stage study for R788, RIGL’s treatment for rheumatoid arthritis; says it hopes to have a partner 1H10. [WSJ]

• Amylin Pharmaceuticals’ (AMLN) trial not so good. [Reuters]

• Good news for Array Biopharma (ARRY) [Pharmaceutical Business Review]

• AstraZeneca (AZN) and MAP Pharmaceuticals (MAPP) break up asthma alliance. [Reuters]

• Selling Tylenol not so hard for J&J. [WSJ]

• No Norvasc patent for Pfizer in Canada. Sorry. [Pharmalive]

• Finally, Wyeth’s Rapamune can make you live longer? OK OK, it just helps mice live longer. Plus, monkeys live longer on fewer calories. [WSJ]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts